Drug development: Longer-lived proteins.
Hubbell
Jeffrey A
JA
D000818:Animals; D015195:Drug Design; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry / Q000493:pharmacokinetics; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics; D011108:Polymers / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000138:chemical synthesis* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011108:Polymers; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a